English Spanish Chinese Russian French Japanese Portuguese Hindi Telugu Tamil

Annalen der klinischen und Laborforschung

  • ISSN: 2386-5180
  • H-Index der Zeitschrift: 17
  • Zitierbewertung der Zeitschrift: 6.26
  • Journal-Impact-Faktor: 5.31
Indiziert in
  • Genamics JournalSeek
  • Nationale Wissensinfrastruktur Chinas (CNKI)
  • CiteFactor
  • Verzeichnis der Indexierung von Forschungszeitschriften (DRJI)
  • Publons
  • Euro-Pub
  • Google Scholar
  • SHERPA ROMEO
  • Geheime Suchmaschinenlabore
Mehr sehen
Teile diese Seite

Abstrakt

Unlocking the Potential of Antibody Drug Conjugates: A Revolutionary Approach to Targeted Cancer Therapy

Sofia Will*

Antibody Drug Conjugates (ADCs) are a promising class of targeted cancer therapies that combine the specificity of monoclonal antibodies with the cytotoxic activity of chemotherapeutic agents. ADCs have the potential to improve cancer treatment by selectively targeting cancer cells, reducing toxicity to healthy tissues, and improving therapeutic outcomes. In this article, we will discuss the mechanism of action of ADCs, their development, and their potential applications in cancer therapy.